As of January 23, 2025, Cingulate (CING) has a market cap of $16.158 million USD. According to our data, Cingulate is ranked No.8688 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $16.16 M |
2.03%
|
Dec 31, 2024 | $15.84 M |
-94.63%
|
Dec 29, 2023 | $0.29 B |
-61.75%
|
Dec 30, 2022 | $0.77 B |
-63.77%
|
Dec 31, 2021 | $2.13 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
ACADIA Pharmaceuticals
ACAD
|
$2.96 B |
-0.000 M
|
USA
|
Axsome Therapeutics
AXSM
|
$4.96 B |
0.000 M
|
USA
|
Intra-Cellular Therapies
ITCI
|
$13.51 B |
-0.000 M
|
USA
|
Sage Therapeutics
SAGE
|
$0.43 B |
-0.000 M
|
USA
|
BioXcel Therapeutics
BTAI
|
$18.04 M |
0.000 M
|
USA
|
Alkermes
ALKS
|
$4.89 B |
-0.000 M
|
Ireland
|
Neurocrine Biosciences
NBIX
|
$14.86 B |
-0.000 M
|
USA
|
Vanda Pharmaceuticals
VNDA
|
$0.25 B |
-0.000 M
|
USA
|
Jazz Pharmaceuticals
JAZZ
|
$7.31 B |
0.000 M
|
Ireland
|
Teva Pharmaceutical Industries
TEVA
|
$24.96 B |
19.808 M
|
Israel
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
Market Cap | = | CING Stock Price | * | CING Shares Outstanding |
= | $5.03 | * | 3.21 M | |
= | $16.16 M |